Humanigen HGEN Stock Price is consolidated and ready for a run? URGENT

hgen

Humanigen HGEN Stock Price has been trying to recover since it’s August high of almost $17.83.

Wondering why this stock is having such a hard time and if it can break the overall trend? Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!


[thrive_leads id=’14274′]

Before we get started, I wanted to introduce myself to you. Hi 🙋‍♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.

I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.

What do I mean by big winners?

Stocks that move more than 100% in a month! HGEN Stock Price could?

Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!

The article is HERE where I shine a spotlight on trending stocks and breakout stocks!

Now, let’s go over some of the basic information on this stock before we get in the technical analysis

Humanigen Inc. Company Information

Company Name: Humanigen Inc.

Ticker: HGEN

Exchange: NASDAQ

Website: https://www.humanigen.com/

Humanigen Inc. Company Summary:

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

HGEN stock price is due to News?

July 6th

announced a peer-reviewed publication in Thorax, one of the world’s leading respiratory medicine journals and the official journal of the British Thoracic Society, describing the role of CRP in identifying patients that derive the greatest benefit of lenzilumab. Participants in the LIVE-AIR study with baseline CRP <150 mg/L treated with lenzilumab demonstrated a 62% reduction in the relative risk of invasive mechanical ventilation and death compared to placebo.1

HGEN 5 Day Chart

HGEN

HGEN Stock Price Technical Analysis:

I like it at $2.40 but not below. It is looking really bad on the 1 month and above charts.

Volume is higher than normal and the technical indicators look good for short term plays.


[thrive_leads id=’14274′]

Skip to content